FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
This article was originally published in The Gray Sheet
Executive Summary
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24